Valuation: Novavax, Inc.

Market Cap 2.11B 1.89B 1.75B 1.6B 3B 200B 3.06B 21.07B 8.24B 104B 7.94B 7.77B 334B P/E 2026 *
-24.7x
P/E 2027 * -154x
Enterprise Value 2.33B 2.08B 1.94B 1.76B 3.31B 221B 3.37B 23.25B 9.1B 115B 8.76B 8.57B 369B EV / Sales 2026 *
5.99x
EV / Sales 2027 * 8.33x
Free-Float
93.06%
Yield 2026 *
-
Yield 2027 * -
1 day+1.42%
1 week+16.44%
Current month+18.59%
1 month+38.89%
3 months+52.08%
6 months+47.53%
Current year+90.77%
1 week 12.18
Extreme 12.18
13.34
1 month 9.61
Extreme 9.61
13.38
Current year 6.76
Extreme 6.76
13.38
1 year 6.2
Extreme 6.2
13.38
3 years 3.53
Extreme 3.5324
23.86
5 years 3.53
Extreme 3.5324
236.5
10 years 3.53
Extreme 3.5324
331.68
Manager TitleAgeSince
Chief Executive Officer 59 23/01/2023
Director of Finance/CFO 60 16/08/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 73 06/08/2010
Director/Board Member 66 01/11/2018
Director/Board Member 60 16/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
6/20/26 A Exercice

Director

37,760 0.0230%
6/18/26 A Free

Director

35,450 0.0216%
4/25/26 A Exercice

Director

19,040 0.0117%
Change 5-day change 1-year change 3-year change Capi.($)
+1.42%+16.44%+43.88%+81.84% 2.11B
+0.21%-4.63%+55.34%+71.32% 68.98B
-0.40%+3.79%+6.30%+60.85% 53.15B
-0.83%+5.24%+9.85%+41.33% 50.83B
+3.45%+4.70%+33.44%+35.96% 44.61B
-2.20%+0.61%+281.88%+532.76% 40.57B
+6.43%+6.84%+18.32%+109.23% 42.53B
+1.28%+1.39%+11.69%+45.10% 30.95B
-0.90%-10.49%+31.48%-1.63% 25.44B
+1.74%-2.02%-13.55%-12.92% 22.66B
Average +1.04%+3.05%+47.86%+96.38% 38.18B
Weighted average by Cap. +0.94%+2.41%+50.56%+103.06%

Financials

2026 *2027 *
Net sales 389M 348M 323M 294M 553M 36.87B 563M 3.88B 1.52B 19.24B 1.46B 1.43B 61.56B 290M 259M 241M 219M 412M 27.49B 420M 2.89B 1.13B 14.34B 1.09B 1.07B 45.9B
Net income -89.44M -79.83M -74.19M -67.49M -127M -8.47B -129M -891M -349M -4.42B -336M -329M -14.14B -14.39M -12.85M -11.94M -10.86M -20.44M -1.36B -20.8M -143M -56.13M -711M -54.02M -52.88M -2.28B
Net Debt 219M 195M 182M 165M 311M 20.74B 317M 2.18B 854M 10.82B 822M 804M 34.63B 303M 271M 252M 229M 430M 28.72B 438M 3.02B 1.18B 14.98B 1.14B 1.11B 47.95B
Projected Income Statement - Annual - Novavax, Inc.
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
15/10/26 $12.82 +1.42% 7,366,883
14/10/26 $12.64 -1.40% 8,545,781
13/10/26 $12.82 +1.26% 8,399,761
12/10/26 $12.66 -0.71% 8,505,452
09/10/26 $12.75 +15.80% 19,026,371
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Novavax, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
12.82USD
Average target price
14.22USD
Spread / Average Target
+10.96%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Novavax, Inc.
  1. Stock Market
  2. Stocks
  3. NVAX Stock